Type 3 hemochromatosis and beta-thalassemia trait

Eur J Haematol. 2004 May;72(5):370-4. doi: 10.1111/j.1600-0609.2004.00230.x.

Abstract

Type 3 hemochromatosis is a rare autosomal recessive disorder due to mutations of the TFR2 gene. We describe clinical, biochemical and histopathologic findings of a patient with type 3 hemochromatosis at presentation and during a follow-up of more than 20 yr and we evaluate the effect of an associated beta-thalassemia trait on phenotypic expression. At the age of 33 yr the patient showed a marked iron overload and severe iron-related complications. After removal of 26 g of iron by subcutaneous deferoxamine infusion a marked clinical improvement was observed. Liver biopsies, performed at the age of 34 and 49 yr, indicate that in type 3 hemochromatosis there is a progressive hepatocellular iron accumulation from Rappaport's zone 1-3 and that iron loading in sinusoidal and portal macrophages occurs only in the more advanced stage. As observed in HFE hemochromatosis, the beta-thalassemia trait seems to aggravate the clinical picture of patients lacking TFR2, favoring higher rates of iron accumulation probably by activation of the erythroid iron regulator.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Substitution
  • Biopsy
  • Cardiomyopathy, Dilated / etiology
  • Chelation Therapy
  • DNA Mutational Analysis
  • Deferoxamine / therapeutic use
  • Disease Progression
  • Exons / genetics
  • Hemochromatosis / complications
  • Hemochromatosis / genetics*
  • Hemochromatosis / pathology
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / drug therapy
  • Iron Overload / etiology
  • Iron Overload / pathology
  • Liver / pathology
  • Liver Cirrhosis / etiology
  • Male
  • Mutation, Missense
  • Receptors, Transferrin / deficiency
  • Receptors, Transferrin / genetics
  • beta-Thalassemia / complications
  • beta-Thalassemia / genetics*
  • beta-Thalassemia / pathology

Substances

  • Iron Chelating Agents
  • Receptors, Transferrin
  • TFR2 protein, human
  • Deferoxamine